Literature DB >> 12604546

Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.

Alasdair P MacGowan1, Chris A Rogers, H Alan Holt, Karen E Bowker.   

Abstract

The pharmacodynamics of moxifloxacin against Streptococcus pneumoniae and Pseudomonas aeruginosa were investigated in a pharmacokinetic infection model. Three strains of S. pneumoniae, moxifloxacin, and two strains of P. aeruginosa were used. Antibacterial effect and emergence of resistance were measured for both species over a 72-h period using an initial inoculum of about 10(8) CFU/ml. At equivalent area under the curve (AUC)/MIC ratios, S. pneumoniae was cleared from the model while P. aeruginosa was not. For S. pneumoniae, the area under the bacterial kill curve up to 72 h could be related to AUC/MIC ratio using an inhibitory maximum effect (E(max)) model (concentration required for 50% E(max) [EC(50)], 45 +/- 22; r(2), 0.97). For P. aeruginosa even at the highest AUC/MIC ratio (427), bacterial clearance was insufficient for the EC(50) to be calculated. Emergence of resistance occurred with P. aeruginosa but not to any significant extent with S. pneumoniae. Emergence of resistance in P. aeruginosa as measured by population analysis profile (PAP-AUC) was dependent on drug exposure and time of exposure. In weighted least-squares regression analysis AUC/MIC ratio was predictive of PAP-AUC. When emergence of resistance was measured by the time for the colony counts on media containing antibiotic to increase by 2 logs, again AUC/MIC was the best predictor of emergence of resistance. However, for both experiments using S. pneumoniae and P. aeruginosa the correlation between all the pharmacodynamic parameters was high. These data indicate that for a given fluoroquinolone the magnitude of the AUC/MIC ratio for antibacterial effect is dependent on the bacterial species. Emergence of resistance is dependent on (i) species, (ii) duration of drug exposure, and (iii) drug exposure. A single AUC/MIC ratio magnitude is not adequate to predict antibacterial effect or emergence of resistance for all bacterial species.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604546      PMCID: PMC149285          DOI: 10.1128/AAC.47.3.1088-1095.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.

Authors:  A MacGowan; C Rogers; H A Holt; M Wootton; K Bowker
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

2.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.

Authors:  E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.

Authors:  A P MacGowan; C A Rogers; H A Holt; M Wootton; K E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Authors:  P D Lister; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

7.  In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.

Authors:  G G Zhanel; M Walters; N Laing; D J Hoban
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

8.  Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.

Authors:  M K Lacy; W Lu; X Xu; P R Tessier; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

9.  Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; O V Kononenko; S H Zinner; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

10.  Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.

Authors:  K J Madaras-Kelly; B E Ostergaard; L B Hovde; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more
  16 in total

1.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.

Authors:  Alasdair P MacGowan; Rosy Reynolds; Alan R Noel; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

4.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 5.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan Noel; Sharon Tomaselli; Heather Elliott; Karen Bowker
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Authors:  Karen E Bowker; Alan R Noel; Sharon G Tomaselli; Heather Elliott; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2012-06-19       Impact factor: 5.191

8.  Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

9.  Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.

Authors:  Tomoyuki Homma; Toshihiko Hori; Giichi Sugimori; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

10.  Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Authors:  Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.